146 related articles for article (PubMed ID: 38204164)
1. α-L-iduronidase fused with humanized anti-human transferrin receptor antibody (lepunafusp alfa) for mucopolysaccharidosis type I: A phase 1/2 trial.
Harmatz P; Giugliani R; Martins AM; Hamazaki T; Kubo T; Kira R; Minami K; Ikeda T; Moriuchi H; Kawashima S; Takasao N; So S; Sonoda H; Hirato T; Tanizawa K; Schmidt M; Sato Y
Mol Ther; 2024 Mar; 32(3):609-618. PubMed ID: 38204164
[TBL] [Abstract][Full Text] [Related]
2. A Phase 2/3 Trial of Pabinafusp Alfa, IDS Fused with Anti-Human Transferrin Receptor Antibody, Targeting Neurodegeneration in MPS-II.
Okuyama T; Eto Y; Sakai N; Nakamura K; Yamamoto T; Yamaoka M; Ikeda T; So S; Tanizawa K; Sonoda H; Sato Y
Mol Ther; 2021 Feb; 29(2):671-679. PubMed ID: 33038326
[TBL] [Abstract][Full Text] [Related]
3. Enzyme replacement with transferrin receptor-targeted α-L-iduronidase rescues brain pathology in mucopolysaccharidosis I mice.
Kida S; Koshimura Y; Yoden E; Yoshioka A; Morimoto H; Imakiire A; Tanaka N; Tanaka S; Mori A; Ito J; Inoue A; Yamamoto R; Minami K; Hirato T; Takahashi K; Sonoda H
Mol Ther Methods Clin Dev; 2023 Jun; 29():439-449. PubMed ID: 37251981
[TBL] [Abstract][Full Text] [Related]
4. Iduronate-2-Sulfatase with Anti-human Transferrin Receptor Antibody for Neuropathic Mucopolysaccharidosis II: A Phase 1/2 Trial.
Okuyama T; Eto Y; Sakai N; Minami K; Yamamoto T; Sonoda H; Yamaoka M; Tachibana K; Hirato T; Sato Y
Mol Ther; 2019 Feb; 27(2):456-464. PubMed ID: 30595526
[TBL] [Abstract][Full Text] [Related]
5. Iduronate-2-sulfatase fused with anti-hTfR antibody, pabinafusp alfa, for MPS-II: A phase 2 trial in Brazil.
Giugliani R; Martins AM; So S; Yamamoto T; Yamaoka M; Ikeda T; Tanizawa K; Sonoda H; Schmidt M; Sato Y
Mol Ther; 2021 Jul; 29(7):2378-2386. PubMed ID: 33781915
[TBL] [Abstract][Full Text] [Related]
6. [Pharmacological property, mechanism of action and clinical study results of Pabinafusp Alfa (Genetical Recombination) (IZCARGO
Yamamoto R; Kawashima S
Nihon Yakurigaku Zasshi; 2022; 157(1):62-75. PubMed ID: 34980815
[TBL] [Abstract][Full Text] [Related]
7. High-dose enzyme replacement therapy in murine Hurler syndrome.
Ou L; Herzog T; Koniar BL; Gunther R; Whitley CB
Mol Genet Metab; 2014 Feb; 111(2):116-22. PubMed ID: 24100243
[TBL] [Abstract][Full Text] [Related]
8. Nonclinical safety evaluation of pabinafusp alfa, an anti-human transferrin receptor antibody and iduronate-2-sulfatase fusion protein, for the treatment of neuronopathic mucopolysaccharidosis type II.
Yamamoto R; Yoden E; Tanaka N; Kinoshita M; Imakiire A; Hirato T; Minami K
Mol Genet Metab Rep; 2021 Jun; 27():100758. PubMed ID: 33981582
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of cerebrospinal fluid heparan sulfate as a biomarker of neuropathology in a murine model of mucopolysaccharidosis type II using high-sensitivity LC/MS/MS.
Tanaka N; Kida S; Kinoshita M; Morimoto H; Shibasaki T; Tachibana K; Yamamoto R
Mol Genet Metab; 2018 Sep; 125(1-2):53-58. PubMed ID: 30064964
[TBL] [Abstract][Full Text] [Related]
10. Clearance of heparan sulfate in the brain prevents neurodegeneration and neurocognitive impairment in MPS II mice.
Morimoto H; Kida S; Yoden E; Kinoshita M; Tanaka N; Yamamoto R; Koshimura Y; Takagi H; Takahashi K; Hirato T; Minami K; Sonoda H
Mol Ther; 2021 May; 29(5):1853-1861. PubMed ID: 33508431
[TBL] [Abstract][Full Text] [Related]
11. Plasma Pharmacokinetics of Valanafusp Alpha, a Human Insulin Receptor Antibody-Iduronidase Fusion Protein, in Patients with Mucopolysaccharidosis Type I.
Pardridge WM; Boado RJ; Giugliani R; Schmidt M
BioDrugs; 2018 Apr; 32(2):169-176. PubMed ID: 29442294
[TBL] [Abstract][Full Text] [Related]
12. Neurocognitive and somatic stabilization in pediatric patients with severe Mucopolysaccharidosis Type I after 52 weeks of intravenous brain-penetrating insulin receptor antibody-iduronidase fusion protein (valanafusp alpha): an open label phase 1-2 trial.
Giugliani R; Giugliani L; de Oliveira Poswar F; Donis KC; Corte AD; Schmidt M; Boado RJ; Nestrasil I; Nguyen C; Chen S; Pardridge WM
Orphanet J Rare Dis; 2018 Jul; 13(1):110. PubMed ID: 29976218
[TBL] [Abstract][Full Text] [Related]
13. Dose-dependent effects of a brain-penetrating iduronate-2-sulfatase on neurobehavioral impairments in mucopolysaccharidosis II mice.
Morimoto H; Morioka H; Imakiire A; Yamamoto R; Hirato T; Sonoda H; Minami K
Mol Ther Methods Clin Dev; 2022 Jun; 25():534-544. PubMed ID: 35662814
[TBL] [Abstract][Full Text] [Related]
14. Targeting of the CNS in MPS-IH using a nonviral transferrin-alpha-L-iduronidase fusion gene product.
Osborn MJ; McElmurry RT; Peacock B; Tolar J; Blazar BR
Mol Ther; 2008 Aug; 16(8):1459-66. PubMed ID: 18523448
[TBL] [Abstract][Full Text] [Related]
15. Intravenous delivery for treatment of mucopolysaccharidosis type I: A comparison of AAV serotypes 9 and rh10.
Belur LR; Podetz-Pedersen KM; Tran TA; Mesick JA; Singh NM; Riedl M; Vulchanova L; Kozarsky KF; McIvor RS
Mol Genet Metab Rep; 2020 Sep; 24():100604. PubMed ID: 32461912
[TBL] [Abstract][Full Text] [Related]
16. Divergent developmental trajectories in two siblings with neuropathic mucopolysaccharidosis type II (Hunter syndrome) receiving conventional and novel enzyme replacement therapies: A case report.
Tomita K; Okamoto S; Seto T; Hamazaki T; So S; Yamamoto T; Tanizawa K; Sonoda H; Sato Y
JIMD Rep; 2021 Nov; 62(1):9-14. PubMed ID: 34765392
[TBL] [Abstract][Full Text] [Related]
17. Enzyme Replacement Therapy with Pabinafusp Alfa for Neuronopathic Mucopolysaccharidosis II: An Integrated Analysis of Preclinical and Clinical Data.
Giugliani R; Martins AM; Okuyama T; Eto Y; Sakai N; Nakamura K; Morimoto H; Minami K; Yamamoto T; Yamaoka M; Ikeda T; So S; Tanizawa K; Sonoda H; Schmidt M; Sato Y
Int J Mol Sci; 2021 Oct; 22(20):. PubMed ID: 34681597
[TBL] [Abstract][Full Text] [Related]
18. Laronidase-loaded liposomes reach the brain and other hard-to-treat organs after noninvasive nasal administration.
Schuh RS; Franceschi EP; Brum BB; Fachel FNS; Poletto É; Vera LNP; Santos HS; Medeiros-Neves B; Monteagudo de Barros V; Helena da Rosa Paz A; Baldo G; Matte U; Giugliani R; Ferreira Teixeira H
Int J Pharm; 2024 Jun; 660():124355. PubMed ID: 38897489
[TBL] [Abstract][Full Text] [Related]
19. Transcranial pulsed ultrasound facilitates brain uptake of laronidase in enzyme replacement therapy for Mucopolysaccharidosis type I disease.
Hsu YH; Liu RS; Lin WL; Yuh YS; Lin SP; Wong TT
Orphanet J Rare Dis; 2017 Jun; 12(1):109. PubMed ID: 28595620
[TBL] [Abstract][Full Text] [Related]
20. RTB lectin-mediated delivery of lysosomal α-l-iduronidase mitigates disease manifestations systemically including the central nervous system.
Ou L; Przybilla MJ; Koniar B; Whitley CB
Mol Genet Metab; 2018 Feb; 123(2):105-111. PubMed ID: 29198892
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
